X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6123) 6123
oncology (3774) 3774
cancer (3538) 3538
female (2873) 2873
pancreatic cancer (2535) 2535
animals (2505) 2505
male (2144) 2144
metastasis (2058) 2058
tumors (1977) 1977
cell line, tumor (1872) 1872
middle aged (1846) 1846
carcinoma (1820) 1820
pancreatic neoplasms - pathology (1794) 1794
prognosis (1637) 1637
aged (1618) 1618
expression (1601) 1601
chemotherapy (1505) 1505
pancreatic neoplasms - drug therapy (1482) 1482
mice (1472) 1472
adenocarcinoma (1351) 1351
gene expression (1342) 1342
apoptosis (1312) 1312
proteins (1286) 1286
research (1233) 1233
carcinoma, pancreatic ductal - pathology (1194) 1194
adult (1169) 1169
cell biology (1134) 1134
survival (1111) 1111
breast cancer (1045) 1045
medical prognosis (1040) 1040
carcinoma, pancreatic ductal - drug therapy (1032) 1032
analysis (1014) 1014
pancreatic neoplasms - metabolism (1009) 1009
cancer therapies (992) 992
care and treatment (989) 989
health aspects (982) 982
development and progression (962) 962
immunohistochemistry (923) 923
surgery (910) 910
gene expression regulation, neoplastic (902) 902
pancreatic neoplasms - genetics (901) 901
signal transduction (900) 900
breast-cancer (887) 887
gemcitabine (872) 872
genetic aspects (854) 854
cell proliferation (849) 849
kinases (848) 848
metastases (820) 820
carcinoma, pancreatic ductal - metabolism (764) 764
biochemistry & molecular biology (738) 738
deoxycytidine - analogs & derivatives (734) 734
carcinoma, pancreatic ductal - genetics (718) 718
aged, 80 and over (707) 707
medicine (700) 700
medicine & public health (694) 694
hepatocellular-carcinoma (690) 690
growth (674) 674
research article (671) 671
gastroenterology & hepatology (669) 669
multidisciplinary sciences (650) 650
pathology (640) 640
biomarkers (639) 639
review (620) 620
mutation (616) 616
patients (615) 615
pancreas (606) 606
studies (602) 602
treatment outcome (601) 601
cancer research (583) 583
cell growth (582) 582
cells (580) 580
stem cells (575) 575
angiogenesis (573) 573
therapy (568) 568
cell cycle (556) 556
mice, nude (550) 550
neoplasm staging (545) 545
antineoplastic agents - pharmacology (538) 538
xenograft model antitumor assays (533) 533
epithelial-mesenchymal transition (528) 528
cell proliferation - drug effects (517) 517
activation (512) 512
medicine, research & experimental (512) 512
medical research (511) 511
biomarkers, tumor - metabolism (510) 510
ductal adenocarcinoma (504) 504
diagnosis (502) 502
proliferation (492) 492
science (486) 486
antineoplastic agents - therapeutic use (485) 485
inhibition (474) 474
lung cancer (470) 470
pancreatic neoplasms - mortality (468) 468
disease progression (467) 467
tumorigenesis (466) 466
pancreatic ductal adenocarcinoma (465) 465
antineoplastic combined chemotherapy protocols - therapeutic use (457) 457
neoplasm invasiveness (456) 456
invasion (453) 453
liver cancer (453) 453
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8003) 8003
Japanese (26) 26
German (17) 17
French (7) 7
Chinese (4) 4
Russian (2) 2
Spanish (2) 2
Czech (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature medicine, ISSN 1546-170X, 2015, Volume 21, Issue 11, pp. 1364 - 1371
Journal Article
International journal of molecular sciences, ISSN 1422-0067, 2017, Volume 18, Issue 7, p. 1338
Journal Article
Cancer science, ISSN 1347-9032, 2017, Volume 108, Issue 3, pp. 478 - 487
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human malignancies... 
Angiogenesis | apoptosis | pancreatic cancer | vasculogenic mimicry | verteporfin | HUMAN CHOLANGIOCARCINOMA | HIPPO PATHWAY | DOWN-REGULATION | ANGIOPOIETIN-2 | CANCER | MOLECULAR PATHWAYS | HEPATOCELLULAR-CARCINOMA | IN-VITRO | ONCOLOGY | POOR-PROGNOSIS | CHEMORESISTANCE | Human Umbilical Vein Endothelial Cells | Cyclin D1 - metabolism | Apoptosis - drug effects | Humans | Male | Phosphoproteins - antagonists & inhibitors | Phosphoproteins - metabolism | DNA-Binding Proteins - metabolism | Pancreatic Neoplasms - drug therapy | Proto-Oncogene Proteins c-bcl-2 - metabolism | Vesicular Transport Proteins - antagonists & inhibitors | Adaptor Proteins, Signal Transducing - antagonists & inhibitors | Verteporfin | Antineoplastic Agents - pharmacology | Cell Survival - drug effects | DNA-Binding Proteins - antagonists & inhibitors | Matrix Metalloproteinase 2 - metabolism | Pancreatic Neoplasms - pathology | Oncogene Proteins - metabolism | Nuclear Proteins - metabolism | Poly (ADP-Ribose) Polymerase-1 - metabolism | Transcription Factors - antagonists & inhibitors | Porphyrins - pharmacology | Carcinoma, Pancreatic Ductal - pathology | Transcription Factors - metabolism | Xenograft Model Antitumor Assays | Carcinoma, Pancreatic Ductal - drug therapy | Animals | Mice, Nude | Neovascularization, Pathologic - drug therapy | Nuclear Proteins - antagonists & inhibitors | Cell Line, Tumor | Cadherins - antagonists & inhibitors | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Cyclin E - metabolism | Adaptor Proteins, Signal Transducing - metabolism | G1 Phase Cell Cycle Checkpoints - drug effects | Antigens, CD | Adenocarcinoma | Proteins | Photochemotherapy | Analysis | Pancreatic cancer | Cancer | Cell proliferation | Metastasis | Cancer therapies | Mimicry | Cell adhesion & migration | Macular degeneration | Cell cycle | Xenografts | G1 phase | Cell survival | Photodynamic therapy | Poly(ADP-ribose) polymerase | Gene expression | Cadherin | Gelatinase A | Yes-associated protein | Microscopy | Medical prognosis | Stem cells | Hypoxia | Apoptosis | Tumors | Original
Journal Article
Cancer cell, ISSN 1535-6108, 2012, Volume 21, Issue 3, pp. 418 - 429
Pancreatic ductal adenocarcinomas (PDAs) are characterized by a robust fibroinflammatory response... 
INTERSTITIAL FLUID PRESSURE | SOLID TUMORS | ONCOLOGY | COMPARING STANDARD PANCREATICODUODENECTOMY | HUMAN OSTEOSARCOMA XENOGRAFTS | RANDOMIZED-TRIAL | HEAD ADENOCARCINOMA | TUMOR VASCULATURE | EXTENDED LYMPHADENECTOMY | CANCER | BLOOD-PRESSURE | CELL BIOLOGY | Adenocarcinoma - pathology | Cell Adhesion Molecules - administration & dosage | Stromal Cells - pathology | Pancreatic Neoplasms - blood supply | Deoxycytidine - pharmacology | Hyaluronic Acid - physiology | Polyethylene Glycols - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Stromal Cells - drug effects | Hyaluronoglucosaminidase - administration & dosage | Drug Evaluation, Preclinical | Hyaluronoglucosaminidase - therapeutic use | Tumor Microenvironment - drug effects | Animals, Genetically Modified | Deoxycytidine - administration & dosage | Pancreatic Neoplasms - pathology | Microvessels - drug effects | Adenocarcinoma - drug therapy | Carcinoma, Pancreatic Ductal - pathology | Extracellular Fluid - drug effects | Polyethylene Glycols - administration & dosage | Adenocarcinoma - blood supply | Hyaluronoglucosaminidase - pharmacology | Carcinoma, Pancreatic Ductal - drug therapy | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hyaluronic Acid - metabolism | Mice | Carcinoma, Pancreatic Ductal - blood supply | Cell Adhesion Molecules - therapeutic use | Deoxycytidine - analogs & derivatives | Enzymes | Medical colleges | Care and treatment | Glycosaminoglycans | Oncology, Experimental | Research | Chemotherapy | Universities and colleges | Drug therapy | Hyaluronic acid | Public health | Tumors | Cancer
Journal Article
Drug Resistance Updates, ISSN 1368-7646, 2015, Volume 23, pp. 55 - 68
Abstract Pancreatic ductal adenocarcinoma (PDA) ranks fourth among cancer related deaths... 
Infectious Disease | Hematology, Oncology and Palliative Medicine | Gemcitabine | Environment mediated drug resistance | Metabolism | Pancreatic ductal adenocarcinoma | Chemoresistance | PHARMACOLOGY & PHARMACY | MicroRNAs - antagonists & inhibitors | Apoptosis - drug effects | Humans | Gene Expression Regulation, Neoplastic | Apoptosis - genetics | MicroRNAs - metabolism | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Neoplasm Proteins - metabolism | Carcinoma, Pancreatic Ductal - genetics | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Carcinoma, Pancreatic Ductal - mortality | MicroRNAs - agonists | Pancreatic Neoplasms - mortality | Neoplasm Proteins - genetics | Tumor Microenvironment - drug effects | Signal Transduction | Pancreatic Neoplasms - pathology | Pancreatic Neoplasms - genetics | Carcinoma, Pancreatic Ductal - pathology | Enzyme Inhibitors - therapeutic use | Carcinoma, Pancreatic Ductal - drug therapy | Drug Resistance, Neoplasm - genetics | Ribonucleotide Reductases - antagonists & inhibitors | Ribonucleotide Reductases - metabolism | Survival Analysis | MicroRNAs - genetics | Ribonucleotide Reductases - genetics | Deoxycytidine - analogs & derivatives | Drug Resistance, Neoplasm - drug effects | Adenocarcinoma | Chemotherapy | Drug resistance | Cancer | Medical research | Pancreatic cancer | Medicine, Experimental | Rankings | Metastasis
Journal Article
Nature medicine, ISSN 1546-170X, 2016, Volume 22, Issue 3, pp. 278 - 287
Journal Article
EMBO Molecular Medicine, ISSN 1757-4676, 02/2017, Volume 9, Issue 2, pp. 167 - 180
Pancreatic ductal adenocarcinoma (PDAC) is considered a non‐immunogenic tumor, and immune checkpoint inhibitor monotherapy lacks efficacy in this disease. Radiotherapy (RT... 
mathematical modeling | pancreatic cancer | PD‐L1 immune checkpoint | liver metastases | radiosensitization | PD-L1 immune checkpoint | MEDICINE, RESEARCH & EXPERIMENTAL | METASTASIS | MYELOID CELLS | RADIATION | BREAST-CANCER | ANTI-PD-L1 ANTIBODY | INHIBITION | TUMOR RADIOSENSITIVITY | IMMUNOTHERAPY | T-CELL-ACTIVATION | MICE | Models, Theoretical | Deoxycytidine - administration & dosage | Carcinoma, Pancreatic Ductal - radiotherapy | Treatment Outcome | Adenocarcinoma - drug therapy | CD8-Positive T-Lymphocytes | Carcinoma, Pancreatic Ductal - drug therapy | Animals | B7-H1 Antigen - antagonists & inhibitors | Radiation-Sensitizing Agents - administration & dosage | Mice | Deoxycytidine - analogs & derivatives | Adenocarcinoma - radiotherapy | Disease Models, Animal | Adenocarcinoma | Liver cancer | Analysis | Immunotherapy | Pancreatic cancer | Liver | Metastasis | T cells | Radiotherapy | Bone grafts | Flow cytometry | Gemcitabine | CD8 antigen | Cytotoxicity | Lymphocytes T | Kinases | Cancer therapies | CD45 antigen | Metastases | CD69 antigen | Cell activation | Radiosensitization | CD44 antigen | Mathematical models | Pancreas | Stat1 protein | Immune system | CD11b antigen | Radiation therapy | Chemotherapy | Immune checkpoint | FasL protein | Immunogenicity | Medical prognosis | Immunology | Digestive System | Cancer
Journal Article
Cancer cell, ISSN 1535-6108, 2014, Volume 25, Issue 6, pp. 735 - 747
Journal Article
Gut, ISSN 0017-5749, 01/2013, Volume 62, Issue 1, pp. 112 - 120
Objective Pancreatic ductal adenocarcinoma (PDA) is characterised by stromal desmoplasia and vascular dysfunction, which critically impair drug delivery... 
INTERSTITIAL FLUID PRESSURE | CELLS | THERAPY | SOLID TUMORS | MICROENVIRONMENT | PERMEABILITY | DUCTAL ADENOCARCINOMA | GASTROENTEROLOGY & HEPATOLOGY | GEMCITABINE | CHEMOTHERAPY | ENDOTHELIAL GROWTH-FACTOR | Immunohistochemistry | Cell Adhesion Molecules - administration & dosage | Tissue Array Analysis | Pancreatic Neoplasms - blood supply | Antineoplastic Agents - administration & dosage | Hyaluronic Acid - physiology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Drug Delivery Systems | Pancreatic Neoplasms - drug therapy | Hyaluronoglucosaminidase - administration & dosage | Carcinoma, Pancreatic Ductal - mortality | Cell Adhesion Molecules - pharmacology | Pancreatic Neoplasms - mortality | Doxorubicin - administration & dosage | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Mice, Transgenic | Treatment Outcome | Biomarkers, Tumor - physiology | Recombinant Proteins - pharmacology | Recombinant Proteins - administration & dosage | Hyaluronoglucosaminidase - pharmacology | Carcinoma, Pancreatic Ductal - drug therapy | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Pancreatic Ductal - physiopathology | Mice | Carcinoma, Pancreatic Ductal - blood supply | Pancreatic Neoplasms - physiopathology | Drug Resistance, Neoplasm - physiology | Deoxycytidine - analogs & derivatives | Drug Resistance, Neoplasm - drug effects | Care and treatment | Blood-vessels | Pancreatic cancer | Patient outcomes | Physiological aspects | Models | Research | Hyaluronic acid | Tumors | Studies | Angiogenesis | Medical research | Medical prognosis | Cytotoxicity | Extracellular matrix | Permeability | Kinases | Vascular endothelial growth factor | stem cells | cell death | cancer vaccines | hyaluronan | epithelial cell growth | cancer immunobiology | drug delivery | matrix | epithelial cell adhesion | cancer genetics | carcinogenesis | pancreatic fibrosis | pharmacology | pharmacokinetics | tumour microenvironment | cancer | fibrosis | pancreatic disease | Original | 1506 | pancreatic tumours | extracellular matrix | oxidative stress
Journal Article